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Abstract 
Introduction: Outbreak reports indicate a risk of cross-infection following medical 
procedures using semi-invasive ultrasound probes (SIUPs). This study aimed to evaluate the 
risk of infection, using microbiological reports and antibiotic prescriptions as proxy 
measures, associated with SIUP procedures, including transoesophageal echocardiography 
(TOE), transvaginal (TV) and transrectal (TR) ultrasound. 
Methods: Patient records from the Electronic Communication of Surveillance in Scotland 
(ECOSS) and the Prescribing Information System (PIS) were linked with the Scottish 
Morbidity Records (SMR) for cases in Scotland between 2010 and 2016. Three retrospective 
cohorts were created to include inpatients/day-cases and outpatients in the following 
specialties: Cardiology, Gynaecology and Urology. Cox regression was used to quantify the 
association between SIUP procedures and the risk of positive microbiological reports and 
community antibiotic prescriptions in the 30-day period following the procedure. 
Results: There was a greater hazard ratio (HR) of microbiological reports for patients who 
had undergone TOE (HR: 4.92; 95% CI: 3.17–7.63), TV (HR: 1.41; 95% CI: 1.21–1.64) and TR 
ultrasound (HR: 3.40; 95% CI: 2.90–3.99), compared with unexposed cohort members after 
adjustment for age, co-morbidities, previous hospital admissions and past care home 
residence. Similarly, there was a greater HR of antibiotic prescribing for those who had 
received TV (HR: 1.26; 95% CI: 1.20–1.32) and TR (HR: 1.75; 95% CI: 1.66–1.84) ultrasound, 
compared with unexposed patients. 
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Conclusion: Analysis of linked national datasets demonstrated a greater risk of infection 
within 30 days of undergoing SIUP procedures, using microbiological reports and antibiotic 
prescriptions as proxy measures of infection.  
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Introduction 
Reports of outbreaks and incidents in the published literature suggest a possible risk of 
cross-infection following medical procedures that involve the use of semi-invasive 
ultrasound probes (SIUPs).1 This risk concerns endocavitary ultrasound probes: 
transoesophageal echocardiography (TOE) probes, transvaginal (TV) probes and transrectal 
(TR) probes; as well as non-endocavitary ultrasound probes when in contact with broken 
skin. Following one particular incident, the UK Medicines and Healthcare products 
Regulatory Agency (MHRA) released a Medical Device Alert in June 2012 in relation to the 
decontamination of SIUPs after the death of a patient from hepatitis B virus infection – an 
event that may have been caused by the failure to appropriately disinfect a TOE probe 
between each patient use.2 This event underscores the clinical importance of establishing 
the infectious risk of semi-invasive ultrasound procedures to support appropriate methods 
of probe decontamination. 
There have been six published outbreaks of healthcare-associated infections related to the 
use of TOE probes since 2003: in the USA,3 4 Japan,5 6 France7 and Switzerland.8 These 
reports included cases of bloodstream infection and pneumonia, associated with 
Pseudomonas aeruginosa and Legionella pneumophila, respectively, as well as positive 
cultures of Enterobacter cloacae, Escherichia coli, Serratia marcescens and Salmonella 
enterica serotype Isangi. Typically, the outbreaks were linked to the use of damaged probes, 
low-level disinfection or contaminated rinse water. There have been no published outbreaks 
associated with TV or TR ultrasound probes, although these procedures are commonly 
employed within outpatient settings and are therefore less likely to be identified as such. 
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Under the Spaulding classification system, endocavitary ultrasound probes that come into 
contact with mucous membranes and non-endocavitary ultrasound probes that touch 
broken skin should both be considered as semi-critical items.9 In April 2016, Health 
Protection Scotland (HPS) and Health Facilities Scotland (HFS) published joint guidance 
recommending the use of high-level disinfection for the decontamination of SIUPs.10 As 
demonstrated by a national survey carried out in 2012, prior to national guidance being 
issued there was considerable variation in practice with regard to methods for cleaning 
SIUPs in Scotland.11 Of the 42 departments that responded, only four (9.5%) departments 
were using high-level disinfection. Similarly, a Europe-wide survey distributed via the 
European Society of Radiology in 2015 found that only 14.7% of respondents reported using 
high-level disinfection for endocavitary probes.12 
This study aimed to use both microbiological and prescribing data as proxy measures to give 
an estimated risk of infection following SIUP procedures in Scotland from 2010 to 2016, 
prior to the publication of national HPS guidance in April 2016 on decontamination of SIUPs. 
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Methods 
Data sources 
Patient-level data on hospitalisation and procedures were obtained from the National 
Services Scotland (NSS) General/Acute Inpatient and Day Case dataset (SMR01) and 
Outpatient Attendance dataset (SMR00).13 Positive microbiological reports were retrieved 
from the NSS Electronic Communication of Surveillance in Scotland (ECOSS) dataset, which 
contains details of micro-organisms and infections identified and reported by microbiology 
laboratories in the National Health Service (NHS) in Scotland.14 Antibiotic prescriptions were 
identified from the NSS Prescribing Information System (PIS), which contains details of all 
NHS medications prescribed and dispensed in the community in Scotland.15 Study data were 
generated during routine care and had all patient identifiers removed prior to analysis. Data 
were linked using the Community Health Index (CHI) number – a unique patient identifier 
used in the NHS.16 NSS Privacy Advisory Committee approval was granted and all data 
linkage and analysis adhered to NSS Information Governance Policy and Procedures. 
 
Cohort identification 
The study created three retrospective cohorts – Cardiology, Gynaecology and Urology – 
covering the period 2010 to 2016 in Scotland. The study cohorts were identified from 
SMR01 and SMR00 datasets. Individuals were assigned to one of these cohorts, based on 
their exposure to certain procedures or hospital episodes/outpatient attendance in selected 
specialties (Table 1), and who were also Scottish residents aged ≥16 as of 1st April 2010 with 
a valid CHI. Patients were included in the Cardiology cohort if they had undergone a TOE 
procedure in the period from 1st April 2010 to 31st March 2016 or if they were a Cardiology 
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inpatient or outpatient in the same time period. Patients were included in the Gynaecology 
cohort if they had a Gynaecology inpatient/day-case episode or an outpatient attendance 
under the Gynaecology specialty, and they were included in the Urology cohort if they had a 
Urology inpatient/day-case episode or an outpatient attendance under the Urology 
specialty. Due to the lack of recording as to which devices had been used, a number of 
procedures were assumed to have involved the use of a TV or TR probe, based upon the 
authors’ knowledge of current best practice for medical procedures (Table 1). 
[Table 1] 
Data extraction 
Following cohort identification, patient-level data for individuals assigned to one of the 
three cohorts were extracted from the data sources. Inpatient/day-case hospital episodes 
and outpatient attendance, including date of SIUP procedure, were obtained from SMR01 
and SMR00 datasets, respectively. For individuals in each of the three cohorts, 
corresponding ECOSS data were extracted to include all microbiological reports of the 
following specimens: blood, upper respiratory and lower respiratory specimens for 
Cardiology specialty attendance/episodes; urine and genital specimens for Gynaecology 
specialty attendance/episodes; and blood, urine, genital and faecal specimens for Urology 
specialty attendance/episodes. However, data on sensitive infections, such as human 
immunodeficiency virus and hepatitis C virus, were not extracted in order to minimise the 
risk of violating patient confidentiality. Mycobacterium tuberculosis was excluded from the 
analysis for having an incubation period greater than 30 days. For individuals in the three 
cohorts, corresponding PIS data were extracted to include all community antibiotic 
prescriptions from the legacy British National Formulary (BNF) Chapter 5.1, Antibacterial 
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Drugs, excluding anti-tuberculosis drugs and anti-leprotic drugs (paragraphs 9 and 10, 
respectively). For Gynaecology specialty attendance/episodes, prescriptions were further 
classified into those agents most commonly used in the treatment of urinary tract infections 
in Scotland: trimethoprim, nitrofurantoin, ciprofloxacin, cefalexin and co-amoxiclav. 
Antibiotics prescribed within 30 days of a previous prescription were assumed to be related 
to the same period of infection and only the first prescription was counted in this period. 
 
From SMR01 data, a Charlson co-morbidity score was calculated, based on the weightings 
outlined by Charlson et al.17 and using the algorithm defined for the International 
Classification of Diseases-10 (ICD-10) codes by Quan et al.18 Diagnostic codes from hospital 
admissions in the five years prior to 1st April 2010 were used to calculate the Charlson score. 
Individuals with no admissions in this period were assigned a score as unknown. SMR01 
data were also used to determine the number of hospital stays the patient had in the 12 
months prior to 1st April 2010. The number of drug classes, defined as the total number of 
medicines prescribed from different paragraphs of the legacy BNF in the 12 months prior to 
1st April 2010, was used as an additional measure of co-morbidity.19 SMR01 and PIS datasets 
were used to identify if a patient was admitted to hospital from a care home location (i.e. a 
long-term care facility in the community providing a supported care environment) in the 12 
months prior to 1st April 2010, or if the patient was registered on the PIS dataset as being in 
a care home at the time of a prescription in the 12 months prior to the beginning of the 
study. This implies a patient was resident in a care home at some point in the 12 months 
prior to the start of the study and should not be interpreted as the patient being resident at 
the time of any possible infection. 
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Data linkage and analysis 
Corresponding microbiological and prescribing data were linked to SIUP procedures using 
the unique patient CHI number within the NHS Scotland Infection Intelligence Platform 
(IIP).20 For both microbiological reports and antibiotic prescriptions, a positive outcome 
linked to a SIUP procedure was defined as a report or prescription in the period from one 
day following the procedure date to 30 days following the procedure. The 30-day period 
was chosen on the basis of standard incubation periods for micro-organisms that are likely 
to pose a risk of cross-infection via SIUPs, as a ‘worst-case’ scenario.21 Individuals in each 
cohort contributed person-time follow-up to the unexposed grouping whilst not exposed to 
a SIUP, starting from the date they entered the cohort (1st April 2010). Individuals exposed 
to a SIUP procedure contributed person-time follow-up to the exposed group from one day 
to 30 days post-procedure. All individuals were followed-up until the end of the study (31st 
March 2016) or date of death, if applicable. Cox proportional hazards was used to compare 
the rate of occurrence of the appropriate outcome (i.e. positive microbiological report or 
antibiotic prescription) in the cohort for the exposed period for each type of SIUP procedure 
against the non-exposed period, to determine the hazard ratio and 95% confidence interval. 
This process was performed independently for both microbiological and prescribing 
outcomes. Unadjusted and fully adjusted analyses were conducted for the following factors: 
age, gender, NHS board of residence, Charlson co-morbidity score, number of hospital 
admissions in past 12 months, number of BNF drug classes prescribed in past 12 months and 
care home residence in past 12 months. A p-value of ≤0.05 was chosen as the threshold for 
statistical significance. Data manipulation was carried out in SPSS (IBM, version 21) and all 
statistical analysis was conducted in R (version 3.2.0) using the survival package.22
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Results 
The number of patients included were 495 786, 330 500 and 156 625 for the Cardiology, 
Gynaecology and Urology cohorts, respectively (Table 2). The number of SIUP procedures 
recorded were 3 364 for TOE, 60 698 for TV ultrasound and 15 934 for TR ultrasound. For 
ECOSS reports, the total number of person-years follow-up was 72 805 743, 53 723 455 and 
24 850 921 for Cardiology, Gynaecology and Urology cohorts, respectively. For PIS 
prescriptions, the total number of person-years follow-up was 72 811 440, 53 723 480 and 
24 850 921 for the same cohorts. The slight difference in person-time follow-up for ECOSS 
and PIS outcomes was due to variation in the number of individuals with a date of death 
prior to the positive outcome (i.e. microbiological reports could be submitted after date of 
death). 
[Table 2] 
Of the Cardiology cohort, 51.6% were male, 27.9% had previously been hospitalised and 
1.1% had been resident in a care home. For the Gynaecology cohort, 16.2% had previously 
been hospitalised and 0.1% had been resident in a care home; as for the Urology cohort, 
23.8% had been hospitalised and 0.6% had been resident in a care home. In addition, 12.3% 
of the Cardiology cohort, 19.2% of the Gynaecology cohort and 22.4% of the Urology cohort 
had not been prescribed any drugs within the past 12 months. Twenty-seven percent of the 
Cardiology cohort had a Charlson score of 1 or higher, as did 7.0% of the Gynaecology 
cohort and 18.6% of the Urology cohort, indicating that the cohorts were relatively healthy. 
Both the Cardiology and Urology cohorts had a higher prevalence of co-morbidities than the 
Gynaecology cohort, in addition to which the Gynaecology cohort was largely younger in 
age. For example, 64.9% of the Gynaecology cohort was below the age of 45, whereas 
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71.1% of the Cardiology cohort and 58.1% of the Urology cohort were aged 55 years or 
older. 
The 30-day incidence rate per 100 000 person-years (p100,000py) of positive 
microbiological reports was raised for those exposed to each type of SIUP procedure, 
compared to those not exposed – TOE exposed 310.90 vs. 63.66 p100,000py; TV exposed 
138.88 vs. 86.13 p100,000py; and TR exposed 494.27 vs. 134.12 p100,000py (Table 3). 
Similarly, the 30-day incidence rate of community antibiotic prescriptions was raised – TOE 
exposed 3497.05 vs. 3250.43 p100,000py; TV exposed 4039.94 vs. 2899.51 p100,000py; and 
TR exposed 4958.81 vs. 2704.94 p100,000py. There was a significant increase (p<0.001) in 
the unadjusted risk of infection for all three types of SIUP procedure, as determined by 
positive microbiological reports and community antibiotic prescriptions.  
The increased risk continued to be statistically significant when the analysis was adjusted for 
confounding factors. A greater adjusted hazard ratio (HR) of positive microbiological reports 
was observed for patients who had undergone TOE (HR: 4.92; 95% CI: 3.17–7.63; p<0.001), 
TV (HR: 1.41; 95% CI: 1.21–1.64; p<0.001) and TR ultrasound (HR: 3.40; 95% CI: 2.90–3.99; 
p<0.001). Similarly, there was a greater adjusted HR of community antibiotic prescribing for 
those who had received TV (HR: 1.26; 95% CI: 1.20–1.32; p<0.001) and TR (HR: 1.75; 95% CI: 
1.66–1.84; p<0.001) ultrasound. The adjusted HR for community antibiotic prescriptions 
following TOE procedures was not found to be significant (HR: 1.05; 95% CI: 0.92–1.20; 
p=0.49). 
[Table 3]
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Discussion 
Through linking national datasets of routinely collected data, we found that exposure to a 
SIUP procedure was associated with an increased risk of infection, as demonstrated by 
raised hazard ratios for both positive microbiological reports and community antibiotic 
prescriptions. To the authors’ knowledge, this is the first study using linkage of national 
datasets to determine the risk of infection associated with SIUP procedures.  
Whilst a range of studies have measured the prevalence of contamination on SIUPs,23-27 few 
have attempted to assess the risk to patients of cross-infection from re-use of contaminated 
probes. Bénet et al.28 conducted a cohort study of 50 244 patients tested for human 
immunodeficiency virus (HIV) and 105 955 patients tested for hepatitis C virus (HCV), 
between 2004 and 2012, in a single university hospital (Lyon, France). Multivariate logistic 
regression models were adjusted for sex, age and time period, to calculate the prevalence of 
HIV and HCV seropositivity. These established that exposure to a SIUP in the past 12 months 
was not associated with an increased risk of seropositivity for HIV (p=0.18) or HCV (p=0.43). 
In a subgroup Cox model analysis of 13 730 and 8232 patients tested for HCV and HIV, the 
incidence of seroconversion was 16.1 and 0 cases per 10 000 patient-years, respectively, 
among patients with exposure to a SIUP in the 12 months before testing. The incidence of 
HIV and HCV seroconversion did not significantly differ according to probe exposure (p=0.64 
and p=0.69). However, fewer than 2000 patients in the full cohort were exposed to SIUPs 
(cf. approx. 80 000 procedures in our study), and the authors did not distinguish between 
TOE, TV and TR ultrasound procedures when reporting incidence rates. In contrast, our 
study used larger cohorts (approx. 150 000 to 500 000) distributed across an entire country, 
including hospitals with different infection rates and decontamination practices. This 
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feature, together with the tendency of bacteria to persist on inanimate surfaces for a longer 
period of time than viruses,29 might explain why our results demonstrated a significantly 
increased risk, whereas the results of Bénet et al. did not. 
The incidence rates calculated from our study are consistent with the risk of infection 
estimated by other published studies, and indicate an increase in absolute risk of 0.05–
2.25% attributable to SIUP exposure. For example, Leroy et al.30 predicted a cross-infection 
risk for TV and TR probes of 0.7–6.0% for selected microbial pathogens, including blood-
borne viruses, human papillomavirus and Chlamydia trachomatis, based on modelling for a 
hypothetical cohort of four million procedures. These risks were based upon estimated 
parameters acquired from published literature. A meta-analysis of 24 cohort studies (total 
of 24 627 patients) has pooled the prevalence of infectious complications following TR 
ultrasound-guided prostate biopsy, indicating an infection risk of 3.1%.31 Both studies have 
been criticised for methodological limitations addressed by our study through the inclusion 
of a multi-site cohort and use of real surveillance data.32 33 
Adjusted hazard ratios were greatest for those undergoing TOE procedures, followed by TR 
ultrasound procedures. The substantially greater hazard ratio for TOE procedures reflects 
the number of infection outbreaks associated with TOE probes in the published literature.3-8 
These patients commonly receive ultrasound examination during an episode of care as an 
inpatient and are likely to be medically compromised with multiple co-morbidities, 
increasing their risk of infection. Therefore, we made statistical adjustments to minimise the 
impact of medical co-morbidities as a confounding factor. Since infective endocarditis is a 
frequent indication for TOE procedures, patients with positive blood cultures or antibiotic 
prescriptions in the 30 days before the procedure were excluded from analysis. TOE probes 
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are commonly used as an operative aid during cardiac surgery – a situation that would be 
expected to heighten the risk of infection – however, we were unable to distinguish 
between critical and non-critical situations using our data sources. 
 
Limitations 
The use of routinely collected data inevitably entailed a number of limitations, such as 
precluding the use of patient-specific data on SIUP decontamination methods; although, it 
allowed the use of larger cohorts than would normally be available for analysis. Positive 
microbiological reports and antibiotic prescriptions are only proxy measures for clinical 
infection and may respectively represent asymptomatic colonisation – as opposed to overt 
infection – or a provisional diagnosis of infection without prior confirmation by 
microbiological culture. Reporting of urine, genital and faecal specimens in ECOSS is not 
mandatory and, since there was significant variation amongst NHS regional boards in 
specimen reporting, this indicates that the infection risk may be under-estimated. Neither is 
it mandatory to record SIUP procedures for inpatients and day-cases unless the patient has 
been specifically admitted for that procedure; therefore, it is possible that some procedures 
will not have been identified in the study cohort. The non-significant difference in antibiotic 
prescriptions for those receiving TOE procedures in the Cardiology cohort is likely to be due 
to these patients undergoing the procedure during an inpatient stay, with the consequence 
that any antibiotic prescriptions will not be recorded in the PIS community prescribing 
dataset. Hospital inpatient prescribing is not currently available as a national dataset. Pre-
surgical antibiotic prophylaxis for needle biopsy of the prostate is recommended by the 
European Association of Urology34 and the American Urological Association,35 and this 
practice could have lowered the infection risk following TR ultrasound. 
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Clinical relevance 
Existing guidelines from HPS,10 the Centers for Disease Control and Prevention,9 the 
American Institute of Ultrasound in Medicine,36 the Australasian Society for Ultrasound in 
Medicine/Australasian College for Infection Prevention and Control,37 the British Society of 
Echocardiography38 and the World Federation for Ultrasound in Medicine and Biology,39 all 
recommend that high-level disinfection is applied for SIUPs, even if a barrier sheath or 
protective cover is used, irrespective of procedure type. This recommendation is based 
upon the observation that sheaths frequently perforate before or during use. Australian 
guidelines strictly encourage the use of sheaths for all procedure types, and sterile sheaths 
for use in critical aseptic fields.37 In Scotland, as in the USA, current guidelines do not 
require the use of a sheath unless it is clinically indicated to aid the diagnostic procedure.10 
Our findings imply that disinfection practices from 2010 to 2016 in Scotland may have been 
inadequate for the re-use of SIUPs, posing a risk of cross-infection; albeit a very low risk. 
Under the precautionary principle, in the event that the risk is low and the consequences 
are high, full scientific certainty should not be used as justification for postponing cost-
effective measures to prevent future infections. Hence, failure to comply with existing 
guidance on disinfection of SIUPs will continue to result in an unacceptable risk of harm to 
patients. 
 
Implications for research 
Future research in this area should initially focus on the reasons for non-compliance with 
national guidance on SIUP decontamination and subsequent evaluation of guideline 
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implementation to determine whether changes in practice are widely adopted and 
sustained. Following this, a prospective cohort study using a similar methodology should be 
conducted to ascertain if national guidance recommending high-level disinfection has 
reduced the risk of infection from SIUP procedures. Ideally, the recording of all SIUP 
procedures in the SMR datasets should become mandatory, which would ensure that data 
are more robust for any future data linkage exercises or national surveillance. Local 
surveillance of infections following SIUP procedures would facilitate the identification of 
future outbreaks, allowing researchers to determine the risk of infection from SIUP 
exposure using clinically confirmed diagnoses. 
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Conclusion 
Analysis of linked national datasets demonstrated a greater risk of positive microbiological 
reports and community antibiotic prescriptions within 30 days for adults who had 
undergone SIUP procedures in Scotland. This finding indicates that, prior to the publication 
in April 2016 of national HPS guidance advocating high-level disinfection, the re-use of SIUPs 
posed an increased risk of infection.  
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Table 1: Inclusion criteria for Cardiology, Gynaecology and Urology cohorts.  
Cardiology cohort 
Inclusion criteria: 
 Cardiology inpatient/day-case episode; General Medicine inpatient/day-case 
episode with Cardiology diagnosis code (ICD10 I20-I25, I26-I28, I30-I52); 
Cardiology outpatient attendance; or procedure code U20.2 Transoesophageal 
echocardiography 
Exposure classed as procedure code: 
 U20.2 Transoesophageal echocardiography 
Gynaecology cohort  
Inclusion criteria: 
 Gynaecology inpatient/day-case episode or outpatient attendance 
Exposure classed as procedure code: 
 Q55.5 Transvaginal ultrasound examination of female genital tract 
 Q51.5 Transvaginal ultrasound guided aspiration of ovarian cyst 
 Q21 Placement/removal of IUD AND U09.2 Ultrasound of pelvis 
 Q48.4 Transvaginal oocyte recovery 
 Q55.9 Unspecified examination of female genital tract AND U09.2 Ultrasound of 
pelvis 
Urology cohort  
Inclusion criteria: 
 Urology inpatient/day-case episode or outpatient attendance 
Exposure classed as procedure code: 
 M70.3 Rectal needle biopsy of prostate 
 M70.6 Radioactive seed implantation into prostate 
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Table 2: Characteristics of Cardiology, Gynaecology and Urology cohorts by age group, 
gender, Charlson score, British National Formulary (BNF) drug classes prescribed, previous 
hospital admissions and past care home residence. 
 Cardiology Cohort Gynaecology Cohort Urology Cohort 
 n % n % n % 
Age group 
 16-24  12 271 2.5  70 698 21.4  9 142 5.8 
 25-34  17 747 3.6  75 033 22.7  13 999 8.9 
 35-44  38 756 7.8  68 607 20.8  19 272 12.3 
 45-54  74 527 15.0  55 645 16.8  23 151 14.8 
 55-64  101 783 20.5  28 385 8.6  33 054 21.1 
 65-74  116 368 23.5  19 674 6.0  33 470 21.4 
 75-84  100 322 20.2  10 497 3.2  20 401 13.0 
 ≥85  34 012 6.9  1 961 0.6  4 136 2.6 
Gender 
 Male  256 031 51.6  0 0.0  156 625 100.0 
 Female  239 750 48.4  330 500 100.0  0 0.0 
Charlson score 
 0  168 085 33.9  121 025 36.6  53 653 34.3 
 1-2  99 945 20.2  19 765 6.0  22 004 14.1 
 3-4  24 206 4.9  1 866 0.6  4 980 3.2 
 ≥5  9 560 1.9  1 303 0.4  1 993 1.3 
 Unknown  193 990 39.1  186 541 56.4  73 995 47.2 
BNF drug classes prescribed 
 0  60 778 12.3  63 476 19.2  35 092 22.4 
 1-4  134 104 27.1  159 761 48.3  56 371 36.0 
 5-9  162 250 32.7  74 959 22.7  40 933 26.1 
 10-14  94 938 19.2  23 444 7.1  17 682 11.3 
 15-19  33 538 6.8  6 816 2.1  5 135 3.3 
 ≥20  10 178 2.1  2 044 0.6  1 412 0.9 
Previous hospital admissions 
 0  357 476 72.1  276 927 83.8  119 320 76.2 
 1  83 053 16.8  39 005 11.8  22 167 14.2 
 2  30 531 6.2  9 133 2.8  7 993 5.1 
 3  12 312 2.5  2 734 0.8  3 409 2.2 
 ≥4  12 414 2.5  2 701 0.8  3 736 2.4 
Past care home residence 
 No  490 478 98.9  330 093 99.9  155 718 99.4 
 Yes  5 308 1.1  407 0.1  907 0.6 
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Table 3: Unadjusted and adjusted hazard ratios (HR), with 95% confidence intervals (CI) and p-values, for Electronic Communication of 
Surveillance in Scotland (ECOSS) positive microbiological reports and Prescribing Information System (PIS) community antibiotic prescriptions 
by transoesophageal echocardiography (TOE), transvaginal (TV) and transrectal (TR) ultrasound procedures. 
 Number of 
events 
Total 
person-
years 
Incidence rate 
per 100 000 
person-years 
Unadjusted Adjusted 
HR (95% CI) p-value HR (95% CI) p-value 
ECOSS reports        
 Cardiology No procedure  46 343  72 799 310 63.66  1.00   Reference   1.00 Reference 
  
 
  TOE procedure  20  6 433 310.90  4.64  (95% CI: 3.00 – 7.20) <0.001  4.92  (95% CI: 3.17 – 7.63) <0.001 
 Gynaecology No procedure  46 167  53 602 489 86.13  1.00   Reference   1.00 Reference 
  
 
  TV procedure  168  120 967 138.88  1.40  (95% CI: 1.20 – 1.63) <0.001  1.41  (95% CI: 1.21 – 1.64) <0.001 
 Urology No procedure  33 289  24 819 966 134.12  1.00   Reference   1.00 Reference 
  
 
  TR procedure  153  30 955 494.27  3.36  (95% CI: 2.87 – 3.94) <0.001  3.40  (95% CI: 2.90 – 3.99) <0.001 
PIS prescriptions        
 Cardiology No procedure  2 366 475  72 805 006 3250.43  1.00   Reference   1.00 Reference  
  TOE procedure  225  6 434 3497.05  0.99  (95% CI: 0.86 – 1.12) 0.827  1.05  (95% CI: 0.92 – 1.20) 0.490 
 Gynaecology No procedure  1 554 212  53 602 513 2899.51  1.00   Reference   1.00 Reference  
  TV procedure  4 887  120 967 4039.94  1.40  (95% CI: 1.34 – 1.47) <0.001  1.26  (95% CI: 1.20 – 1.32) <0.001 
 Urology No procedure  671 366  24 819 966 2704.94  1.00   Reference   1.00 Reference  
  TR procedure  1 535  30 955 4958.81  1.67  (95% CI: 1.59 – 1.76) <0.001  1.75  (95% CI: 1.66 – 1.84) <0.001 
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Table 4 (Supplemental): Cardiology cohort hazard ratios for ECOSS microbiological reports and PIS antibiotic prescriptions by all variables. 
 
Variable 
ECOSS reports PIS prescriptions 
Unadjusted Adjusted Unadjusted Adjusted 
HR (95% CI) HR (95% CI) p-value HR (95% CI) HR (95% CI) p-value 
Procedure      
 No  1.00   Reference  1.00 Reference 
  
  1.00   Reference  1.00 Reference  
 Yes  4.64  (95% CI: 3.00 – 7.20)  4.92  (95% CI: 3.17 – 7.63)  <0.001  0.99  (95% CI: 0.86 – 1.12)  1.05  (95% CI: 0.92 – 1.20)  0.490 
Age group      
 16-24  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 25-34  1.60  (95% CI: 1.40 – 1.83)  1.42  (95% CI: 1.24 – 1.62)  <0.001  1.03  (95% CI: 1.02 – 1.05)  0.95  (95% CI: 0.94 – 0.96)  <0.001 
 35-44  1.80  (95% CI: 1.60 – 2.03)  1.33  (95% CI: 1.17 – 1.50)  <0.001  1.12  (95% CI: 1.11 – 1.13)  0.92  (95% CI: 0.91 – 0.93)  <0.001 
 45-54  2.49  (95% CI: 2.22 – 2.80)  1.50  (95% CI: 1.33 – 1.68)  <0.001  1.22  (95% CI: 1.21 – 1.24)  0.88  (95% CI: 0.87 – 0.89)  <0.001 
 55-64  4.03  (95% CI: 3.60 – 4.52)  2.00  (95% CI: 1.78 – 2.24)  <0.001  1.41  (95% CI: 1.40 – 1.42)  0.89  (95% CI: 0.88 – 0.90)  <0.001 
 65-74  5.39  (95% CI: 4.81 – 6.03)  2.25  (95% CI: 2.01 – 2.52)  <0.001  1.63  (95% CI: 1.61 – 1.64)  0.88  (95% CI: 0.87 – 0.89)  <0.001 
 75-84  5.36  (95% CI: 4.79 – 6.00)  2.11  (95% CI: 1.88 – 2.37)  <0.001  1.72  (95% CI: 1.70 – 1.74)  0.86  (95% CI: 0.85 – 0.87)  <0.001 
 ≥85  5.33  (95% CI: 4.75 – 5.99)  2.20  (95% CI: 1.96 – 2.48)  <0.001  1.84  (95% CI: 1.82 – 1.86)  0.90  (95% CI: 0.89 – 0.91)  <0.001 
 Gender      
 Male  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 Female  0.90  (95% CI: 0.89 – 0.92)  0.77  (95% CI: 0.76 – 0.79)  <0.001  1.53  (95% CI: 1.53 – 1.53)  1.32  (95% CI: 1.32 – 1.32)  <0.001 
 Charlson score      
 0  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 1-2  2.45  (95% CI: 2.39 – 2.51)  1.61  (95% CI: 1.57 – 1.65)  <0.001  1.35  (95% CI: 1.35 – 1.35)  1.04  (95% CI: 1.04 – 1.04)  <0.001 
 3-4  3.58  (95% CI: 3.46 – 3.70)  1.74  (95% CI: 1.68 – 1.80)  <0.001  1.59  (95% CI: 1.58 – 1.60)  1.05  (95% CI: 1.04 – 1.06)  <0.001 
 ≥5  4.63  (95% CI: 4.43 – 4.85)  2.00  (95% CI: 1.91 – 2.10)  <0.001  1.66  (95% CI: 1.65 – 1.68)  1.06  (95% CI: 1.05 – 1.07)  <0.001 
 Unknown  0.76  (95% CI: 0.74 – 0.78)  1.04  (95% CI: 1.01 – 1.07)  0.005  0.68  (95% CI: 0.68 – 0.69)  0.90  (95% CI: 0.90 – 0.90)  <0.001 
 BNF drug classes prescribed      
 0  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
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 1-4  1.39  (95% CI: 1.32 – 1.46)  1.28  (95% CI: 1.21 – 1.34)  <0.001  1.82  (95% CI: 1.81 – 1.84)  1.72  (95% CI: 1.71 – 1.73)  <0.001 
 5-9  2.79  (95% CI: 2.66 – 2.93)  2.07  (95% CI: 1.97 – 2.18)  <0.001  2.80  (95% CI: 2.78 – 2.82)  2.56  (95% CI: 2.54 – 2.57)  <0.001 
 10-14  5.16  (95% CI: 4.92 – 5.42)  3.31  (95% CI: 3.15 – 3.49)  <0.001  4.28  (95% CI: 4.25 – 4.31)  3.74  (95% CI: 3.71 – 3.76)  <0.001 
 15-19  8.75  (95% CI: 8.33 – 9.20)  5.02  (95% CI: 4.75 – 5.30)  <0.001  6.07  (95% CI: 6.03 – 6.11)  5.08  (95% CI: 5.05 – 5.12)  <0.001 
 ≥20  14.16  (95% CI: 13.4 – 15.0)  7.32  (95% CI: 6.89 – 7.79)  <0.001  8.14  (95% CI: 8.07 – 8.21)  6.58  (95% CI: 6.52 – 6.64)  <0.001 
 Previous hospital admissions      
 0  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 1  1.69  (95% CI: 1.66 – 1.73)  1.06 (95% CI: 1.03 – 1.09)  <0.001  1.41  (95% CI: 1.41 – 1.41)  1.01  (95% CI: 1.01 – 1.02)  <0.001 
 2  2.25  (95% CI: 2.18 – 2.33)  1.12  (95% CI: 1.08 – 1.16)  <0.001  1.62  (95% CI: 1.61 – 1.63)  1.02  (95% CI: 1.02 – 1.03)  <0.001 
 3  2.93  (95% CI: 2.80 – 3.05)  1.22  (95% CI: 1.17 – 1.28)  <0.001  1.81  (95% CI: 1.79 – 1.82)  1.03  (95% CI: 1.03 – 1.04)  <0.001 
 ≥4  4.66  (95% CI: 4.50 – 4.83)  1.69  (95% CI: 1.62 – 1.76)  <0.001  2.02  (95% CI: 2.01 – 2.04)  1.08  (95% CI: 1.07 – 1.09)  <0.001 
 Past care home residence      
 No  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 Yes  1.99  (95% CI: 1.83 – 2.16)  1.02 (95% CI: 0.94 – 1.11)  0.615  1.81  (95% CI: 1.78 – 1.83)  1.20  (95% CI: 1.19 – 1.22)  <0.001 
 NHS board of residence      
 GG&C  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 A&A  1.24  (95% CI: 1.19 – 1.28)  1.13 (95% CI: 1.10 – 1.17)  <0.001  0.99  (95% CI: 0.99 – 1.00)  0.99  (95% CI: 0.99 – 1.00)  0.003 
 Borders  0.81  (95% CI: 0.76 – 0.87)  0.87 (95% CI: 0.82 – 0.93)  <0.001  0.85  (95% CI: 0.84 – 0.86)  0.95  (95% CI: 0.94 – 0.96)  <0.001 
 D&G  1.14  (95% CI: 1.08 – 1.20)  1.11 (95% CI: 1.05 – 1.16)  0.001  0.89  (95% CI: 0.88 – 0.89)  0.94  (95% CI: 0.93 – 0.95)  <0.001 
 Fife  0.94  (95% CI: 0.90 – 0.98)  0.93 (95% CI: 0.89 – 0.97)  <0.001  0.91  (95% CI: 0.90 – 0.91)  0.95  (95% CI: 0.95 – 0.96)  <0.001 
 Forth Valley  1.18  (95% CI: 1.13 – 1.24)  1.21 (95% CI: 1.15 – 1.26)  <0.001  0.93  (95% CI: 0.92 – 0.94)  0.97  (95% CI: 0.96 – 0.98)  <0.001 
 Grampian  0.87  (95% CI: 0.84 – 0.91)  0.89 (95% CI: 0.85 – 0.92)  <0.001  0.92  (95% CI: 0.91 – 0.92)  1.00  (95% CI: 1.00 – 1.01)  0.021 
 Highland  0.84  (95% CI: 0.80 – 0.88)  0.86 (95% CI: 0.82 – 0.90)  <0.001  0.84  (95% CI: 0.84 – 0.85)  0.92  (95% CI: 0.91 – 0.92)  <0.001 
 Lanarkshire  0.95  (95% CI: 0.92 – 0.98)  0.96 (95% CI: 0.93 – 0.99)  0.005  1.04  (95% CI: 1.03 – 1.04)  1.04  (95% CI: 1.04 – 1.05)  <0.001 
 Lothian  1.17  (95% CI: 1.13 – 1.20)  1.26 (95% CI: 1.22 – 1.30)  <0.001  0.93  (95% CI: 0.93 – 0.94)  1.03  (95% CI: 1.02 – 1.03)  <0.001 
 Orkney  0.37  (95% CI: 0.30 – 0.47)  0.42 (95% CI: 0.34 – 0.53)  <0.001  0.70  (95% CI: 0.68 – 0.71)  0.84  (95% CI: 0.82 – 0.86)  <0.001 
 Shetland  0.90  (95% CI: 0.75 – 1.08)  0.89 (95% CI: 0.74 – 1.07)  0.208  0.87  (95% CI: 0.85 – 0.89)  0.95  (95% CI: 0.92 – 0.97)  <0.001 
 Tayside  1.12  (95% CI: 1.08 – 1.17)  1.19 (95% CI: 1.14 – 1.23)  <0.001  0.91  (95% CI: 0.91 – 0.92)  0.99  (95% CI: 0.98 – 0.99)  <0.001 
 WI  1.02  (95% CI: 0.88 – 1.17)  0.95 (95% CI: 0.82 – 1.09)  0.440  0.98  (95% CI: 0.97 – 1.00)  0.99  (95% CI: 0.97 – 1.01)  0.451 
GG&C = Greater Glasgow & Clyde; A&A = Ayrshire & Arran; D&G = Dumfries & Galloway; WI = Western Isles.
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Table 5 (Supplemental): Gynaecology cohort hazard ratios for ECOSS microbiological reports and PIS antibiotic prescriptions by all variables. 
 
Variable 
ECOSS reports PIS prescriptions 
Unadjusted Adjusted Unadjusted Adjusted 
HR (95% CI) HR (95% CI) p-value HR (95% CI) HR (95% CI) p-value 
Procedure      
 No  1.00   Reference  1.00 Reference 
  
  1.00   Reference  1.00 Reference  
 Yes  1.40  (95% CI: 1.20– 1.63)  1.41  (95% CI: 1.21 – 1.64)  <0.001  1.40  (95% CI: 1.34 – 1.47)  1.26  (95% CI: 1.20 – 1.32)  <0.001 
Age group      
 16-24  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 25-34  0.85  (95% CI: 0.82 – 0.88)  0.79  (95% CI: 0.77 – 0.82)  <0.001  0.91  (95% CI: 0.90 – 0.91)  0.84  (95% CI: 0.83 – 0.84)  <0.001 
 35-44  1.01  (95% CI: 0.97 – 1.04)  0.85  (95% CI: 0.82 – 0.88)  <0.001  1.00  (95% CI: 0.98 – 1.00)  0.83  (95% CI: 0.83 – 0.84)  <0.001 
 45-54  1.30  (95% CI: 1.26 – 1.35)  1.02  (95% CI: 0.98 – 1.05)  0.290  1.10  (95% CI: 1.09 – 1.11)  0.86  (95% CI: 0.85 – 0.87)  <0.001 
 55-64  2.63  (95% CI: 2.54 – 2.72)  1.68  (95% CI: 1.62 – 1.74)  <0.001  1.56  (95% CI: 1.54 – 1.58)  1.05  (95% CI: 1.04 – 1.06)  <0.001 
 65-74  4.63  (95% CI: 4.48 – 4.78)  2.53  (95% CI: 2.44 – 2.62)  <0.001  2.31  (95% CI: 2.29 – 2.34)  1.30  (95% CI: 1.29 – 1.31)  <0.001 
 75-84  6.63  (95% CI: 6.40 – 6.87)  3.32  (95% CI: 3.20 – 3.46)  <0.001  2.72  (95% CI: 2.69 – 2.75)  1.35  (95% CI: 1.33 – 1.37)  <0.001 
 ≥85  10.22  (95% CI: 9.61 – 10.9)  5.00  (95% CI: 4.69 – 5.33)  <0.001  3.32  (95% CI: 3.24 – 3.40)  1.56  (95% CI: 1.53 – 1.60)  <0.001 
 Charlson score      
 0  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 1-2  2.26  (95% CI: 2.20 – 2.33)  1.07  (95% CI: 1.04 – 1.10)  <0.001  1.53  (95% CI: 1.52 – 1.54)  0.92  (95% CI: 0.92 – 0.93)  <0.001 
 3-4  4.58  (95% CI: 4.32 – 4.87)  1.29  (95% CI: 1.21 – 1.37)  <0.001  2.17  (95% CI: 2.13 – 2.22)  0.89  (95% CI: 0.87 – 0.91)  <0.001 
 ≥5  3.23  (95% CI: 2.96 – 3.53)  1.36  (95% CI: 1.24 – 1.49)  <0.001  1.53  (95% CI: 1.48 – 1.59)  0.87  (95% CI: 0.84 – 0.90)  <0.001 
 Unknown  0.59  (95% CI: 0.58 – 0.60)  0.83  (95% CI: 0.82 – 0.85)  <0.001  0.58  (95% CI: 0.58 – 0.59)  0.80  (95% CI: 0.79 – 0.80)  <0.001 
 BNF drug classes prescribed      
 0  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 1-4  1.55  (95% CI: 1.50 – 1.61)  1.36  (95% CI: 1.32 – 1.41)  <0.001  1.78  (95% CI: 1.76 – 1.80)  1.69  (95% CI: 1.67 – 1.71)  <0.001 
 5-9  3.21  (95% CI: 3.10 – 3.33)  2.09  (95% CI: 2.01 – 2.17)  <0.001  3.34  (95% CI: 3.31 – 3.37)  2.88  (95% CI: 2.85 – 2.91)  <0.001 
 10-14  5.69  (95% CI: 5.48 – 5.92)  2.88  (95% CI: 2.76 – 3.00)  <0.001  5.72  (95% CI: 5.66 – 5.79)  4.48  (95% CI: 4.43 – 4.54)  <0.001 
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 15-19  9.28  (95% CI: 8.87 – 9.71)  4.03  (95% CI: 3.84 – 4.24)  <0.001  8.20  (95% CI: 8.09 – 8.31)  6.16  (95% CI: 6.07 – 6.25)  <0.001 
 ≥20  11.28  (95% CI: 10.6 – 12.0)  4.95  (95% CI: 4.62 – 5.30)  <0.001  11.35  (95% CI: 11.2 – 11.6)  8.46  (95% CI: 8.29 – 8.63)  <0.001 
 Previous hospital admissions      
 0  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 1  1.69  (95% CI: 1.66 – 1.73)  1.04 (95% CI: 1.01 – 1.06)  0.013  1.61  (95% CI: 1.60 – 1.62)  1.02  (95% CI: 1.02 – 1.03)  <0.001 
 2  2.25  (95% CI: 2.18 – 2.33)  1.14  (95% CI: 1.09 – 1.19)  <0.001  2.09  (95% CI: 2.06 – 2.11)  1.07  (95% CI: 1.06 – 1.09)  <0.001 
 3  2.93  (95% CI: 2.80 – 3.05)  1.21  (95% CI: 1.14 – 1.29)  <0.001  2.52  (95% CI: 2.47 – 2.57)  1.10  (95% CI: 1.08 – 1.13)  <0.001 
 ≥4  4.66  (95% CI: 4.50 – 4.83)  1.44  (95% CI: 1.35 – 1.53)  <0.001  2.71  (95% CI: 2.66 – 2.77)  1.16  (95% CI: 1.14 – 1.19)  <0.001 
 Past care home residence      
 No  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 Yes  7.52  (95% CI: 6.63 – 8.53)  1.66 (95% CI: 1.46 – 1.89)  <0.001  3.49 (95% CI: 3.33 – 3.66)  1.36  (95% CI: 1.29 – 1.42)  <0.001 
 NHS board of residence      
 GG&C  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 A&A  5.63  (95% CI: 5.44 – 5.83)  5.14 (95% CI: 4.96 – 5.32)  <0.001  1.00  (95% CI: 0.99 – 1.02)  0.98  (95% CI: 0.97 – 0.99)  <0.001 
 Borders  3.47  (95% CI: 3.27 – 3.68)  4.02 (95% CI: 3.80 – 4.27)  <0.001  0.77  (95% CI: 0.76 – 0.79)  0.87  (95% CI: 0.86 – 0.89)  <0.001 
 D&G  5.14  (95% CI: 4.90 – 5.39)  5.00 (95% CI: 4.76 – 5.24)  <0.001  0.88  (95% CI: 0.87 – 0.90)  0.91  (95% CI: 0.89 – 0.92)  <0.001 
 Fife  2.89  (95% CI: 2.77 – 3.01)  2.97 (95% CI: 2.85 – 3.10)  <0.001  0.94  (95% CI: 0.92 – 0.95)  0.97  (95% CI: 0.96 – 0.98)  <0.001 
 Forth Valley  0.53  (95% CI: 0.48 – 0.58)  0.61 (95% CI: 0.55 – 0.67)  <0.001  0.91  (95% CI: 0.90 – 0.93)  0.99  (95% CI: 0.98 – 1.01)  0.423 
 Grampian  5.34  (95% CI: 5.16 – 5.52)  5.64 (95% CI: 5.45 – 5.83)  <0.001  0.87  (95% CI: 0.87 – 0.88)  0.96  (95% CI: 0.95 – 0.97)  <0.001 
 Highland  3.36  (95% CI: 3.23 – 3.50)  3.30 (95% CI: 3.17 – 3.44)  <0.001  0.88  (95% CI: 0.87 – 0.89)  0.92  (95% CI: 0.91 – 0.93)  <0.001 
 Lanarkshire  3.59  (95% CI: 3.46 – 3.72)  3.61 (95% CI: 3.49 – 3.75)  <0.001  1.05  (95% CI: 1.04 – 1.06)  1.02  (95% CI: 1.01 – 1.03)  <0.001 
 Lothian  0.29  (95% CI: 0.27 – 0.31)  0.34 (95% CI: 0.32 – 0.37)  <0.001  0.92  (95% CI: 0.91 – 0.93)  1.06  (95% CI: 1.05 – 1.07)  <0.001 
 Orkney  5.87  (95% CI: 5.23 – 6.60)  5.10 (95% CI: 4.54 – 5.73)  <0.001  0.89  (95% CI: 0.84 – 0.94)  0.90  (95% CI: 0.85 – 0.95)  <0.001 
 Shetland  5.09  (95% CI: 4.47 – 5.81)  5.06 (95% CI: 4.44 – 5.77)  <0.001  0.88  (95% CI: 0.84 – 0.93)  0.90  (95% CI: 0.85 – 0.95)  <0.001 
 Tayside  1.27  (95% CI: 1.20 – 1.34)  1.21 (95% CI: 1.15 – 1.28)  <0.001  0.93  (95% CI: 0.92 – 0.94)  0.95  (95% CI: 0.94 – 0.96)  <0.001 
 WI  7.13  (95% CI: 6.60 – 7.71)  6.32 (95% CI: 5.85 – 6.83)  <0.001  1.04  (95% CI: 1.00 – 1.08)  0.99  (95% CI: 0.95 – 1.02)  0.445 
GG&C = Greater Glasgow & Clyde; A&A = Ayrshire & Arran; D&G = Dumfries & Galloway; WI = Western Isles.
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Table 6 (Supplemental): Urology cohort hazard ratios for ECOSS microbiological reports and PIS antibiotic prescriptions by all variables. 
 
Variable 
ECOSS reports PIS prescriptions 
Unadjusted Adjusted Unadjusted Adjusted 
HR (95% CI) HR (95% CI) p-value HR (95% CI) HR (95% CI) p-value 
Procedure      
 No  1.00   Reference  1.00 Reference 
  
  1.00   Reference  1.00 Reference  
 Yes  3.36  (95% CI: 2.87– 3.94)  3.40  (95% CI: 2.90 – 3.99)  <0.001  1.67  (95% CI: 1.59 – 1.76)  1.75  (95% CI: 1.66 – 1.84)  <0.001 
Age group      
 16-24  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 25-34  1.35  (95% CI: 1.20 – 1.53)  1.30  (95% CI: 1.15 – 1.46)  <0.001  1.00  (95% CI: 0.98 – 1.01)  0.95  (95% CI: 0.94 – 0.97)  <0.001 
 35-44  2.23  (95% CI: 2.00 – 2.48)  1.95  (95% CI: 1.75 – 2.17)  <0.001  1.18  (95% CI: 1.16 – 1.19)  1.00  (95% CI: 0.98 – 1.01)  0.873 
 45-54  3.76  (95% CI: 3.39 – 4.17)  2.91  (95% CI: 2.62 – 3.23)  <0.001  1.48  (95% CI: 1.46 – 1.50)  1.06  (95% CI: 1.05 – 1.08)  <0.001 
 55-64  4.93  (95% CI: 4.46 – 5.46)  3.31  (95% CI: 2.99 – 3.67)  <0.001  1.69  (95% CI: 1.67 – 1.72)  1.05  (95% CI: 1.04 – 1.07)  <0.001 
 65-74  7.20  (95% CI: 6.51 – 7.97)  4.20  (95% CI: 3.79 – 4.65)  <0.001  1.98  (95% CI: 1.95 – 2.01)  1.06  (95% CI: 1.05 – 1.08)  <0.001 
 75-84  11.48  (95% CI: 10.4 – 12.7)  6.07  (95% CI: 5.48 – 6.73)  <0.001  2.33 (95% CI: 2.30 – 2.36)  1.13  (95% CI: 1.12 – 1.15)  <0.001 
 ≥85  18.14  (95% CI: 16.3 – 20.2)  9.49  (95% CI: 8.49 – 10.6)  <0.001  2.68  (95% CI: 2.63 – 2.73)  1.29  (95% CI: 1.26 – 1.31)  <0.001 
 Charlson score      
 0  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 1-2  1.82  (95% CI: 1.76 – 1.87)  1.13  (95% CI: 1.10 – 1.17)  <0.001  1.42  (95% CI: 1.41 – 1.43)  1.04  (95% CI: 1.03 – 1.05)  <0.001 
 3-4  3.25  (95% CI: 3.11 – 3.39)  1.45  (95% CI: 1.39 – 1.52)  <0.001  1.80  (95% CI: 1.78 – 1.82)  1.08  (95% CI: 1.06 – 1.09)  <0.001 
 ≥5  4.12  (95% CI: 3.87 – 4.38)  1.77  (95% CI: 1.66 – 1.90)  <0.001  1.93  (95% CI: 1.90 – 1.97)  1.13  (95% CI: 1.11 – 1.15)  <0.001 
 Unknown  0.65  (95% CI: 0.63 – 0.67)  0.92  (95% CI: 0.89 – 0.94)  <0.001  0.67  (95% CI: 0.66 – 0.67)  0.87  (95% CI: 0.87 – 0.88)  <0.001 
 BNF drug classes prescribed      
 0  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 1-4  1.66  (95% CI: 1.59 – 1.73)  1.21  (95% CI: 1.16 – 1.26)  <0.001  1.79  (95% CI: 1.78 – 1.81)  1.69  (95% CI: 1.68 – 1.71)  <0.001 
 5-9  3.26  (95% CI: 3.13 – 3.39)  1.67  (95% CI: 1.60 – 1.75)  <0.001  2.84  (95% CI: 2.82 – 2.87)  2.49  (95% CI: 2.47 – 2.52)  <0.001 
 10-14  5.03  (95% CI: 4.82 – 5.24)  2.19  (95% CI: 2.08 – 2.29)  <0.001  4.19  (95% CI: 4.15 – 4.23)  3.50  (95% CI: 3.46 – 3.53)  <0.001 
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 15-19  7.07  (95% CI: 6.72 – 7.44)  2.79  (95% CI: 2.63 – 2.95)  <0.001  5.73  (95% CI: 5.67 – 5.80)  4.63  (95% CI: 4.57 – 4.69)  <0.001 
 ≥20  8.99  (95% CI: 8.35 – 9.68)  3.42  (95% CI: 3.16 – 3.71)  <0.001  7.16  (95% CI: 7.04 – 7.29)  5.67  (95% CI: 5.57 – 5.78)  <0.001 
 Previous hospital admissions      
 0  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 1  1.66  (95% CI: 1.62 – 1.71)  1.04 (95% CI: 1.00 – 1.07)  0.026  1.46  (95% CI: 1.45 – 1.47)  1.00  (95% CI: 0.99 – 1.01)  0.970 
 2  2.15  (95% CI: 2.07 – 2.24)  1.07  (95% CI: 1.02 – 1.12)  0.002  1.72  (95% CI: 1.70 – 1.73)  1.01  (95% CI: 1.00 – 1.02)  0.007 
 3  2.72  (95% CI: 2.57 – 2.87)  1.18  (95% CI: 1.11 – 1.25)  <0.001  1.97  (95% CI: 1.95 – 2.00)  1.07  (95% CI: 1.06 – 1.09)  <0.001 
 ≥4  3.90  (95% CI: 3.72 – 4.08)  1.54  (95% CI: 1.46 – 1.62)  <0.001  2.17  (95% CI: 2.14 – 2.20)  1.08  (95% CI: 1.07 – 1.10)  <0.001 
 Past care home residence      
 No  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 Yes  7.07  (95% CI: 6.57 – 7.60)  3.24 (95% CI: 3.01 – 3.49)  <0.001  2.43 (95% CI: 2.37 – 2.49)  1.40  (95% CI: 1.36 – 1.44)  <0.001 
 NHS board of residence      
 GG&C  1.00   Reference  1.00 Reference   1.00   Reference  1.00 Reference  
 A&A  0.80  (95% CI: 0.74 – 0.86)  3.07 (95% CI: 2.95 – 3.19)  <0.001  0.95  (95% CI: 0.94 – 0.96)  0.99  (95% CI: 0.98 – 1.00)  0.015 
 Borders  0.85  (95% CI: 0.81 – 0.90)  2.30 (95% CI: 2.14 – 2.48)  <0.001  0.97  (95% CI: 0.95 – 0.98)  1.01  (95% CI: 0.99 – 1.03)  0.363 
 D&G  0.58  (95% CI: 0.56 – 0.61)  2.37 (95% CI: 2.24 – 2.51)  <0.001  1.01  (95% CI: 0.99 – 1.02)  1.01  (95% CI: 0.99 – 1.02)  0.327 
 Fife  0.29  (95% CI: 0.27 – 0.31)  2.01 (95% CI: 1.93 – 2.10)  <0.001  0.87  (95% CI: 0.86 – 0.87)  0.97  (95% CI: 0.96 – 0.98)  <0.001 
 Forth Valley  0.94  (95% CI: 0.91 – 0.98)  0.98 (95% CI: 0.91 – 1.05)  0.595  0.91  (95% CI: 0.90 – 0.92)  0.98  (95% CI: 0.97 – 0.99)  0.002 
 Grampian  0.33  (95% CI: 0.32 – 0.34)  2.96 (95% CI: 2.85 – 3.08)  <0.001  0.93  (95% CI: 0.92 – 0.94)  1.01  (95% CI: 1.00 – 1.02)  0.011 
 Highland  0.61  (95% CI: 0.58 – 0.64)  1.81 (95% CI: 1.72 – 1.91)  <0.001  0.88  (95% CI: 0.87 – 0.89)  0.92  (95% CI: 0.91 – 0.93)  <0.001 
 Lanarkshire  0.79  (95% CI: 0.77 – 0.83)  2.41 (95% CI: 2.32 – 2.51)  <0.001  1.11  (95% CI: 1.10 – 1.12)  1.09  (95% CI: 1.09 – 1.10)  <0.001 
 Lothian  0.22  (95% CI: 0.21 – 0.23)  0.69 (95% CI: 0.65 – 0.73)  <0.001  1.00  (95% CI: 0.99 – 1.01)  1.06  (95% CI: 1.05 – 1.07)  <0.001 
 Orkney  1.14  (95% CI: 0.94 – 1.39)  3.28 (95% CI: 2.70 – 3.99)  <0.001  0.97  (95% CI: 0.91 – 1.03)  1.02  (95% CI: 0.96 – 1.09)  0.472 
 Shetland  0.89  (95% CI: 0.67 – 1.17)  2.88 (95% CI: 2.19 – 3.79)  <0.001  0.94  (95% CI: 0.87 – 1.01)  0.96  (95% CI: 0.89 – 1.04)  0.297 
 Tayside  0.32  (95% CI: 0.30 – 0.34)  1.09 (95% CI: 1.03 – 1.16)  0.004  0.88  (95% CI: 0.87 – 0.89)  1.00  (95% CI: 0.99 – 1.01)  0.606 
 WI  1.14  (95% CI: 1.01 – 1.28)  2.89 (95% CI: 2.56 – 3.26)  <0.001  1.03  (95% CI: 0.99 – 1.07)  0.96  (95% CI: 0.92 – 0.99)  0.023 
GG&C = Greater Glasgow & Clyde; A&A = Ayrshire & Arran; D&G = Dumfries & Galloway; WI = Western Isles. 
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